Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000774528 | SCV000908231 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-04-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002534147 | SCV002954983 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2022-02-21 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 108 of the BRCA2 protein (p.Asn108Lys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 28528518). ClinVar contains an entry for this variant (Variation ID: 629814). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |